N
Enterprise & Investor Portal

Pilot Partnership Dashboard

Real-time commercial traction and risk registry for Nilus Lab.

Active Pilots
12
▲ +4 this month
Avg. POC Duration
4.2 Weeks
vs. 12wk Industry Avg.
Conversion Rate
82%
POC to Enterprise License
Projected ARR (2026)
$4.8M
Targeted Expansion

Partnership Funnel

Initial Technical Inquiry
Tier-1 Pharma / Stealth Biotech
48
Top of Funnel
Technical Diligence Call
Architecture & Data Provenance Review
22
Diligence Phase
Active Proof-of-Concept (POC)
Live Benchmarking on Partner Targets
12
Value Validation
Enterprise MSA / License
Full Platform Integration
4
Closed Deals

Growth Trajectory

Risk Register (Q1 Update)

Scientific Reproducibility Low

Potential for stochastic drift in un-seeded runs.

Mitigation: Validated Compute Mode (Seed 0x771A) enforced for clinical diligence.
Regulatory Classification Medium

Risk of being classified as SaMD vs. RUO tool.

Mitigation: Explicit Intended Use Statement and Regulatory Boundary published.
Dataset Biases (HCA V3) Medium

Reference dataset may lack specific pathological diversity.

Mitigation: Cross-validation with CZI CELLxGENE pathological sub-manifolds.
Clinical Validation Latency High

In-vitro to In-vivo correlation timelines are extended.

Mitigation: Accelerating ex-vivo organoid validation via Robotic Bridge.

Diligence Summary

Nilus Lab is currently **Institutional Ready**. 100% of top claims are mapped to source artifacts. Zero mismatch between legal terms and GTM motion.

Investment Posture: ALPHA EXPOSURE